Indaptus Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $9.3M | $7.3M | $7.6M | $6.3M | $2.5M | $2.7M |
| SG&A Expense | — | $10.5M | $8.1M | $8.8M | $8.6M | $5.2M | $944.2K |
| Operating Income | — | $-19.8M | $-15.4M | $-16.4M | $-14.9M | $-7.7M | $-3.6M |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | $-20.8M | $-15.0M | — | — | — | — |
| Income Tax Expense | — | $1.7K | $1.7K | $2.5K | $30 | $1.7K | $800 |
| Net Income | — | $-20.8M | $-15.0M | $-15.4M | $-14.3M | $-7.7M | $-3.6M |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-21.58 | $-14.99 | $-0.61 | $-0.58 | $-0.32 | $-0.31 |
| EPS (Diluted) | — | $-21.58 | $-14.99 | $-0.61 | $-0.58 | $-0.32 | $-0.31 |
| Shares Outstanding (Basic) | 2.2M | 966.1K | 1.0M | 25.2M | 24.8M | 24.5M | 11.7M |
| Shares Outstanding (Diluted) | 2.2M | 966.1K | 1.0M | 25.2M | 24.8M | 24.5M | 11.7M |
| Dividends Per Share | — | — | — | — | — | — | — |